The projected twelve-month stock price for Akebia Therapeutics (AKBA) compiled from Wall Street analyst estimates centers around an average target of 3.75 to 4.00 dollars per share. Forecast ranges span from a low estimate of 1.00 dollar up to an optimistic peak of 6.00 dollars. Analysts formulate these predictions by evaluating the revenue trajectory of Vafseo, cost-management efficiency, cash runway, and anticipated catalysts from clinical trials. Because biotechnology equities are subject to sharp fluctuations based on regulatory news and earnings releases, actual price movements may deviate from these consensus targets.